Karyopharm's Net Loss Widens in Q2, Selinexor sNDA for Myelofibrosis on Track

Karyopharm Therapeutics Inc. (KPTI) announced its second-quarter 2026 financial results, reporting a significant increase in its net loss compared to the previous year. Concurrently, the company provided an update on its progress towards submitting a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for its myelofibrosis drug, Selinexor. These developments highlight the company's strategic focus and liquidity position.

For the second quarter, Karyopharm's net loss expanded to $67.0 million, up from $37.3 million in the second quarter of 2025. Diluted loss per share stood at $2.32. Total revenue for the quarter was $33.4 million, a decrease from $37.9 million in the prior-year period. This decline was primarily attributed to the conclusion of development-related expense reimbursements from its partnership with Menarini at the end of 2025. Conversely, U.S. net product revenue for XPOVIO (selinexor) saw a slight increase to $30.8 million from $29.7 million, and royalty revenue from international partners rose from $1.6 million to $2.5 million.

A key highlight for Karyopharm was the update on its myelofibrosis program for Selinexor. The company reconfirmed its plan to submit an sNDA to the FDA in August 2026 for accelerated approval of selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis. This submission is supported by compelling results from the Phase 3 SENTRY trial, which demonstrated a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) at week 24, along with promising overall survival signals. The FDA has provided feedback indicating that SVR35 appears to qualify as a reasonably likely surrogate endpoint (RLSE) to predict overall survival. Karyopharm intends to request Priority Review at the time of submission.

Market analysts view the potential approval of Selinexor for myelofibrosis as a significant growth driver for Karyopharm. If approved, the selinexor plus ruxolitinib combination could become the first approved combination therapy for myelofibrosis patients, targeting a multi-billion-dollar U.S. market. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million, with U.S. XPOVIO net product revenue expected to be between $115 million and $130 million. However, liquidity remains a significant concern, as Karyopharm expects its existing cash and investments to fund operations only into September 2026, with a $15.8 million term-loan payment due on September 10.

The company has been taking steps to manage operational expenses, reporting reductions in research and development (R&D) and selling, general, and administrative (SG&A) expenses. However, Karyopharm decided to reduce investment in its endometrial cancer program following the failure of the Phase 3 XPORT-EC-042 trial to meet its primary endpoint. This strategic shift indicates a reallocation of resources towards more promising areas such as myelofibrosis and multiple myeloma.

Looking ahead, the most critical expectation for Karyopharm is the FDA's decision on Selinexor for myelofibrosis and its subsequent impact on the company's financial health. Analysts project that if accelerated approval is granted, the product could launch as early as the first quarter of 2027. Karyopharm is actively evaluating financing and strategic alternatives to extend its cash runway and maximize shareholder value, which will be crucial for its future growth trajectory.